Insights
Search Results
Client Highlights
1.12.26
Wilson Sonsini Advises Crinetics on Patent Matters Related to Public Offering
On January 6, 2026, Crinetics Pharmaceuticals, a pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors, announced the pricing of an underwritten public offering of 7,620,000 shares of its common stock at a price to the public of $45.95 per share. All of the shares to be sold in the offering are to be sold by Crinetics, and the gross proceeds from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be approximately $350 million. Wilson Sonsini Goodrich & Rosati advised Crinetics on patent matters related to the public offering.
Client Highlights
10.15.24
Wilson Sonsini Advises Crinetics Pharmaceuticals on Patent Matters Related to Upsized $500 Million Common Stock Offering
On October 8, 2024, Crinetics Pharmaceuticals, a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, announced the pricing of an upsized underwritten public offering of 10 million shares of its common stock at a price to the public of $50.00 per share. The gross proceeds to Crinetics from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be $500 million. In addition, Crinetics has granted the underwriters a 30-day option to purchase up to an additional 1.5 million shares of common stock. Wilson Sonsini Goodrich & Rosati is advising Crinetics on patent matters related to the transaction.
Client Highlights
5.15.24
Wilson Sonsini Advises Reneo Pharmaceuticals on IP Matters Related to OnKure Merger
On May 13, 2024, Reneo Pharmaceuticals, Inc. and OnKure, Inc., a privately-held, clinical-stage biopharmaceutical company focused on the development of novel precision medicines in oncology, announced that they have entered into a definitive merger agreement to combine the companies in an all-stock transaction. The combined company will focus on advancing OnKure’s pipeline candidates targeting oncogenic mutations in phosphoinositide 3-kinase alpha (PI3Kα), including its lead program OKI-219, which is currently in a Phase 1 clinical trial for the treatment of solid tumors. Upon completion of the transaction, the combined company is expected to operate under the name OnKure Therapeutics, Inc., and trade on the Nasdaq Global Market under the ticker symbol “OKUR.” The merger is expected to close in 2024.
Client Highlights
4.28.21
Wilson Sonsini Advises Amplyx on IP Matters Related to Acquisition by Pfizer
On April 28, 2021, Pfizer Inc. announced that it has acquired Amplyx Pharmaceuticals, Inc., a privately held company dedicated to the development of therapies for debilitating and life-threatening diseases that affect people with compromised immune systems. Amplyx’s lead compound, Fosmanogepix (APX001), is a novel investigational asset under development for the treatment of invasive fungal infections. In addition to Fosmanogepix, with this acquisition, Pfizer has secured ownership of Amplyx's early-stage pipeline that includes potential antiviral (MAU868) and antifungal (APX2039) therapies. Wilson Sonsini Goodrich & Rosati advised Amplyx on IP matters related to the transaction.
Client Highlights
4.14.21
Wilson Sonsini Advises Reneo Pharmaceuticals on Patent Matters Related to IPO
On April 8, 2021, Reneo Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare, genetic, mitochondrial diseases, announced the pricing of its initial public offering of 6,250,000 shares of its common stock at a public offering price of $15.00 per share, for total gross proceeds of approximately $93.8 million, before deducting underwriting discounts and commissions and offering expenses. All of the shares were offered by Reneo. The shares began trading on the Nasdaq Global Market on April 9, 2021, under the symbol “RPHM.” The underwriters were granted a 30-day option to purchase up to an additional 937,500 shares of common stock at the public offering price less underwriting discounts and commissions. The offering closed on April 13, 2021.
Client Highlights
4.13.21
Wilson Sonsini Advises Crinetics on Patent Matters Related to $75 Million Common Stock Offering
On April 12, 2021, Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, announced that it has closed its previously announced underwritten follow-on offering of 4,562,044 shares of its common stock at a price to the public of $16.44 per share. The gross proceeds to Crinetics from the offering, before deducting the underwriting discounts and commissions and other offering expenses, were approximately $75 million.
Client Highlights
1.08.21
Wilson Sonsini Advises Blacksmith Medicine on IP Matters Related to Its Launch and Collaboration with Lilly
On January 8, 2021, Blacksmith Medicines, Inc., a biotechnology company focused on creating novel medicines for immuno-oncology and inflammatory diseases by targeting human metalloenzymes, announced that it has secured seed funding and has entered into a research collaboration with Eli Lilly and Company (Lilly). Lilly joins existing Blacksmith investors Evotec A.G., MP Healthcare Partners, MagnaSci Ventures, and Alexandria Venture Investments. Blacksmith is a spin-out of Forge Therapeutics, a leading antibiotic discovery company discovering therapies to combat the rise of drug resistance. Wilson Sonsini Goodrich & Rosati advised Blacksmith Medicines on IP matters related to the transactions.
Client Highlights
3.25.20
Wilson Sonsini Advises Forge Therapeutics in Collaboration with Roche to Develop Novel Antibiotic to Treat Lung Infections
On March 25, 2020, Forge Therapeutics (Forge) announced that they have entered into a research collaboration and option agreement with Hoffmann-La Roche (Roche) to license a novel antibiotic for treatment of serious lung infections. Under the terms of the agreement, Roche has an exclusive option to license the antibiotic from Forge. Forge will retain control of the program prior to Roche exercising its option, at which time Roche will take over the further development. Forge is eligible to receive up to $190.5 million in total payments, including potential sales-based payments and royalties upon commercialization of the program. Wilson Sonsini Goodrich & Rosati represented Forge Therapeutics in the transaction.